Figure 4From: Pitavastatin in cardiometabolic disease: therapeutic profilePitavastatin increases high-molecular-weight adiponectin levels. In patients with Metabolic syndrome, the percentage change from baseline in high-molecular-weight (HMW) adiponectin levels is significantly greater in pitavastatin-treated patients achieving ≥10% increase in high-density lipoprotein-cholesterol (HDL-C) levels (PREMIUM study). Adapted from [51].Back to article page